Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Halperin

Showing results (511-520 of 544) with videos related to

Pageof 55
Sort By:
JAMA|May 2, 2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialSimon R M Dobson, Shelly McNeil, Marc Dionne, et al.
The Pediatric Infectious Disease Journal|May 29, 2025
Severity of COVID-19 in Hospitalized Immunocompromised Children Across CanadaCostanza Di Chiara, Tilmann Schober, Daniel S Farrar, et al.
JAMA Network Open|October 4, 2023
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 PandemicMalou Bourdeau, Nirma Khatri Vadlamudi, Nathalie Bastien, et al.
Human Vaccines|October 3, 2006
Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract researchScott A Halperin, David Scheifele, Bernard Duval, et al.
Vaccine|March 21, 2026
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trialAdora Rooyakkers, Lingyun Ye, Pedro E Cahn, et al.
The Journal of Pediatrics|January 31, 2026
Outcomes and Multimorbidity among Children and Youth with Chronic Neurologic Disorders Hospitalized for COVID-19: A Canadian Immunization Monitoring Program, ACTive StudyDaniel S Farrar, Ryan S Huang, Elizabeth J Donner, et al.
BMC Public Health|December 1, 2025
Engaging families to create a better post-pandemic future: semi-structured interviews with youth and parents in CanadaJeanna Parsons Leigh, Stephana Julia Moss, Sara J Mizen, et al.
Lancet (London, England)|December 26, 2021
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trialScott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, et al.
Pediatric Research|January 24, 2025
Pediatric COVID-19 severity by SARS-CoV-2 lineage and vaccine status in Canada: an IMPACT studyDaniel S Farrar, Julie A Bettinger, Aaron J Campigotto, et al.
BMJ Open|June 27, 2023
Codesigning a user-centred digital psychoeducational tool for youth mental well-being with families in Canada: study protocol for a sequential exploratory mixed methods studyStephana Julia Moss, Nicole Racine, Sofia Ahmed, et al.
Pageof 55

Showing results (511-520 of 544) with videos related to

Sort By:
Pageof 55
JAMA|May 2, 2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialSimon R M Dobson, Shelly McNeil, Marc Dionne, et al.
The Pediatric Infectious Disease Journal|May 29, 2025
Severity of COVID-19 in Hospitalized Immunocompromised Children Across CanadaCostanza Di Chiara, Tilmann Schober, Daniel S Farrar, et al.
JAMA Network Open|October 4, 2023
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 PandemicMalou Bourdeau, Nirma Khatri Vadlamudi, Nathalie Bastien, et al.
Human Vaccines|October 3, 2006
Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract researchScott A Halperin, David Scheifele, Bernard Duval, et al.
Vaccine|March 21, 2026
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trialAdora Rooyakkers, Lingyun Ye, Pedro E Cahn, et al.
The Journal of Pediatrics|January 31, 2026
Outcomes and Multimorbidity among Children and Youth with Chronic Neurologic Disorders Hospitalized for COVID-19: A Canadian Immunization Monitoring Program, ACTive StudyDaniel S Farrar, Ryan S Huang, Elizabeth J Donner, et al.
BMC Public Health|December 1, 2025
Engaging families to create a better post-pandemic future: semi-structured interviews with youth and parents in CanadaJeanna Parsons Leigh, Stephana Julia Moss, Sara J Mizen, et al.
Lancet (London, England)|December 26, 2021
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trialScott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, et al.
Pediatric Research|January 24, 2025
Pediatric COVID-19 severity by SARS-CoV-2 lineage and vaccine status in Canada: an IMPACT studyDaniel S Farrar, Julie A Bettinger, Aaron J Campigotto, et al.
BMJ Open|June 27, 2023
Codesigning a user-centred digital psychoeducational tool for youth mental well-being with families in Canada: study protocol for a sequential exploratory mixed methods studyStephana Julia Moss, Nicole Racine, Sofia Ahmed, et al.
Pageof 55